ClinicaliQ Trial Snapshot
- A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) — Recruiting • Phase III • NCT05912517.
- Nipocalimab versus placebo for preventing severe haemolytic disease in at-risk pregnancies.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn. Conditions: Hemolytic Disease of the Fetus and Newborn Interventions: Nipocalimab, Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 120 participants